AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$NOVT

Glastra Matthijs sold $479K of NOVT

Glastra Matthijs (Chief Executive Officer) sold 2,841 shares of NOVANTA INC (NOVT) at $168.76 ($0.48M total) on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jun 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
medium confidence
Mentioned
$NOVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

Traders may monitor whether insider selling accelerates or coincides with other negative signals, but this filing alone does not change fundamentals.

02

Market read

A disclosed insider sale in NOVT under a 10b5-1 plan provides a sentiment datapoint without new operational information.

03

What to watch

Insider selling can be offset by other insider buys or broader institutional flows, which are not covered here.

Relevance 6/10Novelty 4/10Timing: Filed after-hours (2026-06-04) for a sale executed on 2026-06-02.

Background

SEC Form 4 disclosures report insider transactions by officers/directors/10% owners; 10b5-1 plans are pre-arranged trading schedules.

Company-level read

Ticker impact

$NOVTNeutralMedium confidence
Context

Novanta CEO Glastra Matthijs sold $479K of NOVT shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely sentiment-driven and limited given the disclosed 10b5-1 plan.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale (reducing interpretive signal). The filing provides a concrete datapoint (size, date, remaining shares) but no new company-specific operating news.

Market effects

Sector

Minimal; single-company insider sale with no sector-wide regulatory/earnings catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be routine liquidity planning and may not reflect bearish expectations.

Key entities

  • issuer
    Novanta Inc

    Subject of the insider transaction disclosure; CEO sold shares under a 10b5-1 plan.

  • insider
    Glastra Matthijs

    CEO/director who executed the open-market sale.

Read at source← All news

Related articles

AUG 5
$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

leaderpost.com6 min
AUG 5
$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 novt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and

SEC EDGAR 8-K6 min
JUL 27
$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

leaderpost.com5 min
JUN 10
$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

finance.yahoo.com7 min